PDF factsheet
      Z

pentasaccharide in thrombosis prevention for orthopedic surgery , clinical trials results

extended prophylaxis versus standard prophylaxis
PENTHIFRA–PLUS (Eriksson), 2003
25-31 days of fondaparinux 2.5-mg once-daily
versus
6-8 days of fondaparinux 2.5-mg once-daily
patients undergoing hip fracture surgerydouble blind
Follow-up duration: 19-23 days
fondaparinux versus enoxaparin
L8541, 0
fondaparinux 2.5mg subcutaneous once-daily for 7+/-2 days
versus
enoxaparin 40mg s.c. once-daily
chinese patients undergoing major orthopaedic surgery of the lower limbssingle-blind
Follow-up duration: 9 days (49d)
China
L8635, 0
Fondaparinux 2.5mg once daily subcutaneously for 7 days
versus
enoxaparin 40mg once daily SC for 7 days
Taiwanese patients undergoing elective knee replacementopen, blind assessment
Follow-up duration: 10 days
Taiwan
PENTAMAKS (Bauer), 2001
fondaparinux 2.5-mg once-daily subcutaneous, starting 6 hours after surgery
versus
enoxaparin 30mg twice daily (North america recommendation)
elective major knee surgerydouble blind
Follow-up duration: 11 days
North america
PENTHIFRA (Eriksson), 2001
fondaparinux 2.5-mg once-daily subcutaneous, starting 6 hours after surgery
versus
enoxaprin 40mg once daily
hip fracture surgerydouble blind
Follow-up duration: 11 days
21 countries
EPHESUS (Lassen), 2002
fondaparinux 2.5-mg once-daily subcutaneous, starting 6 hours after surgery
versus
enoxaprin 40mg once daily
elective hip replacement surgerydouble blind
Follow-up duration: 11 days (6 weeks)
16 European countries
PENTATHLON (Turpie), 2002
fondaparinux 2.5-mg once-daily subcutaneous, starting 6 hours after surgery
versus
enoxaparin 30mg twice daily (North america recommendation)
elective hip replacement surgerydouble blind
Follow-up duration: 11 days
USA, Canada, Australia
Turpie, 2001
pentasaccharide Org31540/SR90107A subcutaneous once daily at doses 0.75 mg, 1.5 mg, 3.0 mg, 6.0 mg, and 8.0 mg
versus
enoxaparin 30mg once daily subcutaneous
patients undergoing total hip replacementdouble blind
Follow-up duration: >15 days
US, Canada, Autralia
fondaparinux versus placebo
DRI4757, 0
fondaparinux subcutaneously at 0.75, 1.5, 2.5, and 3.0 mg for at least 10 calendar days, (with a maximum of 14 days)
versus
placebo
Japanese patients undergoing elective total knee replacement surgerydouble blind
Follow-up duration: 14 days
Japan
SR123781A versus enoxaparin
DRIVE, 2008
NCT00338897
SR123781A for 5-10 days, doses ranging from 0.25 to 4.0 mg daily for 10 days
versus
enoxaparin 40 mg
patients undergoing total hip replacement surgerydouble blind
Follow-up duration: 5-10 days
12 countries

  Options


in first

in second

  Filter